Languages  By theme  By sector  By country
Page : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - ...
SANOFI-AVENTIS [FR0000120578/SAN]   
[02/08/2013]

SANOFI-AVENTIS : Online Availability of Sanofi Group’s Half-Year Financial Report for 2013

PRESS RELEASE Online Availability of Sanofi Group's Half-Year Financial Report for 2013 Paris, France - August 2, 2013 - Sanofi (EURONEXT : SAN ; NYSE : SNY) announces that its half-year financial report for the period ending June 30, 2013 is now available and has been filed with the French market regulator Autorité des marchés financiers (AMF) and submitted to the U.S. Securities... See more
 
SANOFI-AVENTIS [FR0000120578/SAN]   
[01/08/2013]

SANOFI-AVENTIS : Q2 2013: Last Quarter with Significant Negative Impact from the Patent Cliff

RELEASE PRESS RELEASE Paris, August 1, 2013 Q2 2013: Last Quarter with Significant Negative Impact from the Patent Cliff Change ... See more
 
SANOFI-AVENTIS [FR0000120578/SAN]   
[01/08/2013]

SANOFI-AVENTIS : FDA Advisory Committee Recommends Approval of Sanofi’s Nasacort® AQ Nasal Spray for Over-the-Counter Use

PRESS RELEASE FDA Advisory Committee Recommends Approval of Sanofi's Nasacort(r) AQ Nasal Spray for Over-the-Counter Use - Treats Seasonal and Year-round Nasal Allergy Symptoms in Adults and Children - Paris, France, July 31, 2013 - Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that the U.S. Food and Drug... See more
 
SANOFI-AVENTIS [FR0000120578/SAN]   
[31/07/2013]

SANOFI-AVENTIS : Sanofi Appoints Carsten Hellmann and David Meeker to the Executive Committee

PRESS RELEASE Sanofi Appoints Carsten Hellmann and David Meeker to the Executive Committee Paris, France - July 31, 2013 - Sanofi (EURONEXT: SAN and NYSE: SNY) announced today the appointment of two new members to the Executive Committee, effective September 1st , 2013. Carsten Hellmann joins Sanofi from Chr. Hansen Holding A/S and will take the position of Executive Vice President... See more
 
SANOFI-AVENTIS [FR0000120578/SAN]   
[15/07/2013]

SANOFI-AVENTIS : Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Reg

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l'Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofi a French société anonyme with a registered... See more
 
SANOFI-AVENTIS [FR0000120578/SAN]   
[28/06/2013]

SANOFI-AVENTIS : Genzyme Receives Positive CHMP Opinion for LEMTRADA™ (alemtuzumab) in Europe

PRESS RELEASE Genzyme Receives Positive CHMP Opinion for LEMTRADA(TM) (alemtuzumab) in Europe - CHMP also Recommends NAS Designation for AUBAGIO(r) (teriflunomide) Following Positive Opinion on Approval in March 2013 - - Positive Opinions Set Stage for Introduction of Two New Genzyme Therapies... See more
 
SANOFI-AVENTIS [FR0000120578/SAN]   
[28/06/2013]

SANOFI-AVENTIS : Lyxumia® is first diabetes therapy of its class approved in Japan for use in combination with basal insulin

PRESS RELEASE Lyxumia(r) is first diabetes therapy of its class approved in Japan for use in combination with basal insulin - First once-daily prandial GLP-1 receptor agonist offering a new treatment option for Japanese people living with type 2 diabetes - Paris, France - June 28, 2013 - Sanofi (EURONEXT : SAN and NYSE : SNY) announced... See more
 
Page : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - ...
Videos
Gestionnaires,
Emetteurs,
My favourite companies
Most read news of SANOFI-AVENTIS
Dissemination technology Webdisclosure.com - copyright 2020 SYMEX ECONOMICS all rights reserved